Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy — Masatoshi Kudo (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy
Shared by
Masatoshi Kudo
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy
Editorial Material
2023
en
Authors
Masatoshi Kudo
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2024
Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma
Masatoshi Kudo
Article
2016
Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis
Satoshi Kitai
,
Masatoshi Kudo
,
Naoshi Nishida
,
Namiki Izumi
,
Michiie Sakamoto
,
Yutaka Matsuyama
,
Takafumi Ichida
,
Osamu Nakashima
,
Osamu Matsui
,
Yonson Ku
,
Norihiro Kokudo
,
Masatoshi Makuuchi
Editorial Material
2023
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
Masatoshi Kudo
Editorial Material
2023
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Masatoshi Kudo
Article
1999
Locoregional treatments for hepatocellular carcinoma
Jordi Bruix
,
Josep M. Llovet
Best Practice & Research Clinical Gastroenterology
Discussion(0)
No comments yet. Be the first to comment.